E16: Benzodiazepine-refractory status epilepticus
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
E16: Benzodiazepine-refractory status epilepticus
-
Letto da:
-
Di:
Send us Fan Mail
In this episode of 'EMERGE in EM,' Dr. Mohamed Hagahmed and ICU doctor Dr. Obi Anozie discuss the critical neurological emergency of benzodiazepine-refractory status epilepticus (BRSE). They explore the pathology behind why BRSE occurs, the necessary aggressive treatment strategies, and second-line agent options including levetiracetam, valproic acid, fosphenytoin, propofol, and ketamine. They emphasize the importance of correct dosing, timely escalation of treatment, and thorough patient examination. The conversation also covers the need for a comprehensive approach to non-convulsive status epilepticus and the practical aspects of pre-hospital and ED management, including the use of paralytic agents like rocuronium over succinylcholine.
Paper reference: Pelletier J, Merriman W, Koyfman A, Long B. Benzodiazepine-refractory status epilepticus: A narrative review. Am J Emerg Med. 2025;81:228-235. doi:10.1016/j.ajem.2025.01.046.
If you enjoyed this episode, please follow, subscribe, and leave a review—it helps us reach more listeners.
📱 Connect with me for more educational content, clinical pearls, podcast clips, and behind-the-scenes updates:
- Instagram: @HagahmedMD
- YouTube: @HagahmedMD
Thank you for being part of the EMERGE in EM community. Until next time, stay curious, keep learning, and continue to EMERGE.